Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs)
$108.45
pos +0.00
+0.00%
Today's Range: 104.64 - 109.49 | GILD Avg Daily Volume: 14,893,300
Last Update: 12/19/14 - 3:59 PM EST
Volume: 0
YTD Performance: 44.41%
Open: $0.00
Previous Close: $105.54
52 Week Range: $63.50 - $116.83
Oustanding Shares: 1,508,664,333
Market Cap: 159,224,433,705
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 13 12 12 12
Moderate Buy 2 2 2 1
Hold 3 3 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.44 1.47 1.38 1.33
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 18.71
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
18.71 18.70 25.85
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
2.35% 47.69% 478.86%
GROWTH 12 Mo 3 Yr CAGR
Revenue 15.50 0.41 0.12
Net Income 18.80 0.06 0.02
EPS 10.80 0.18 0.06
Earnings for GILD:
EBITDA 4.87B
Revenue 11.20B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $2.36 $3.49 $7.91 $11.88
Number of Analysts 1 1 1 1
High Estimate $2.36 $3.49 $7.91 $11.88
Low Estimate $2.36 $3.49 $7.91 $11.88
Prior Year $0.52 $1.44 $1.92 $7.91
Growth Rate (Year over Year) 353.85% 142.36% 311.98% 50.19%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
There had been no catalysts.

Biotech Holding Up Real Money Pro($)

But looks like the second-worst weekly loss of the year.

Three Large-Cap Growth Stocks Real Money Pro($)

I would pick up some large caps on any significant dips.

Still Bullish on Apple Real Money Pro($)

Forget the bears. I'd buy on a dip.
An immense market rotation is happening.
Update
Dec 03, 2014 | 7:25 AM EST
Piper Jaffray Healthcare Conference (Day 2 of 2) - 12/02/14 - 12/03/14 New York City,
The market seems to be severely discounting DynaVax's chances of approval for its hep-B treatment.

Buy Gilead Sciences Real Money Pro($)

Its prospects exploded with a breakthrough drug.
Gilead and YY are poised for potential climbs.

Gilead Down Real Money Pro($)

On Hep C data.

Columnist Conversations

3 insiders sold a total of 518,620 Starbucks (SBUX) shares for proceeds of $43.449 MM. 4 insiders dumped 558,1...
Yum Brands saw both insider buying and selling reported last week. One insider bought 10,000 shares for about ...
The bearish star cluster on the Starbucks (SBUX) chart that I highlighted last week preceded price action this...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.